FDA proxies don't coincide with better disease outcomes: Yale study

Yale and Emory researchers question the effectiveness of using FDA drug proxies in the approval process, finding weak associations with disease outcomes.

Related Keywords

United States , American , Joseph Ross , Yale School Of Medicine , Journal Of The American Medical Association , Emory University , New Haven , Yale School , Atlanta Based Emory University , American Medical Association ,